Milestone Pharmaceuticals Inc. (MIST)

Compare

0.8031

+0.0431

+(5.67%)

At close: 4:00:01 PM EDT

0.7800

-0.02

(-2.88%)

After hours: 5:19:00 PM EDT

MIST Stock Falls 66% Following Complete Response Letter for Cardamyst

Milestone Pharmaceuticals faces an FDA setback for its PSVT nasal spray. The company coordinates with regulatory authorities to resolve CRL issues.

Zacks 2 hours ago

MIST
+5.67%
Milestone Pharmaceuticals downgraded to Hold from Buy at TD Cowen

TD Cowen downgraded Milestone Pharmaceuticals (MIST) to Hold from Buy and suspended the firm’s price target after Milestone announced the FDA issued a Complete Response Letter regarding its New Drug Application for Cardamyst nasal spray for the conversion of acute episodes of PSVT to sinus rhythm in adults. The CRL is “upending imminent launch plans” and timelines to NDA resubmission remain unclear given new concerns on FDA functionality, says the analyst, who adds that commercialization prospec

TipRanks 8 hours ago

MIST
+5.67%
TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty

Investing.com -- TD Securities downgraded Milestone Pharmaceuticals (NASDAQ:MIST) to "Hold" and suspended its price target, citing regulatory uncertainty and commercialization challenges for its lead drug, etripamil, following a Complete Response Letter from the U.S. Food and Drug Administration.The FDA issued a Complete Response Letter for MIST’s etripamil New Drug Application for paroxysmal supraventricular tachycardia (pSVT), citing chemistry, manufacturing, and controls issues. While no safe

Investing.com yesterday

MIST
+5.67%
Milestone CRL affirms integrity of clinical data, says H.C. Wainwright

H.C. Wainwright keeps a Buy rating on Milestone Pharmaceuticals (MIST) after the company announced receipt of a complete response letter from the FDA regarding its new drug application for its etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia. While “disappointed,” the firm says the issues raised were exclusively related to chemistry, manufacturing, and controls, with no concerns cited around the clinical efficacy or safety of etripamil. This reaffirms the integr

TipRanks 4 days ago

MIST
+5.67%
FDA Issues Complete Response Letter for Etripamil for PSVT

CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024 MONTREAL and CHARLOTTE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for CARDAMYST™ (etripamil) nasal spray, a prescription medication in development for the conver

GlobeNewswire 5 days ago

MIST
+5.67%
Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology

MONTREAL and CHARLOTTE, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present a moderated poster presentation at the American College of Cardiology annual meeting (ACC25), to be held March 29th to 31st, 2025 in Chicago, Illinois. “This presentation highlights the potential ability of etripamil to successfully c

GlobeNewswire 13 days ago

MIST
+5.67%
Milestone Pharmaceuticals: Q4 Earnings Snapshot

MONTREAL (AP) — Milestone Pharmaceuticals Inc. MIST) on Thursday reported a loss of $12.4 million in its fourth quarter. On a per-share basis, the Montreal-based company said it had a loss of 19 cents.

Associated Press Finance 20 days ago

MIST
+5.67%
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update

FDA PDUFA review goal date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) Assuming FDA approval, proposed launch in PSVT targeted for mid-2025 Milestone well-capitalized to commercialize upon approval with royalty financing MONTREAL and CHARLOTTE, N.C., March 13, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the fourth quarter and full year ended December 31, 2024 and provi

GlobeNewswire 20 days ago

MIST
+5.67%
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MONTREAL and CHARLOTTE, N.C., March 04, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 94,000 options (the “Options”) to purchase the Company’s common shares, pursuant to the Company’s 2021 Inducement Plan (the “Plan”), previously approved by the Company’s Compensation Committee and the Board of Directors, as a material inducement to employment of four new hir

GlobeNewswire 29 days ago

MIST
+5.67%
Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

MONTREAL and CHARLOTTE, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto, will present at the TD Cowen 45th Annual Health Care Conference, to take place from March 3-5, 2025 in Boston. A live webcast of the fireside chat will be available to conference participants on March 4th at 9:10 AM EST. The webcast is available to watch both live and replay for approximately 90-days following the presentation in the

GlobeNewswire last month

MIST
+5.67%
Milestone Pharmaceuticals Gets Notice of Allowance for US Patent on Etripamil Nasal Spray

Milestone Pharmaceuticals (MIST) said Wednesday it received notice of allowance from the US Patent a

PREMIUM
MT Newswires last month

MIST
+5.67%
Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil

Extends US patent protection until 2042MONTREAL and CHARLOTTE, N.C., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it has received Notice of Allowance from the United States Patent and Trademark Office (USPTO) on a new Method of Use patent for etripamil nasal spray (proposed trade name CARDAMYST™), its lead investigational pr

GlobeNewswire last month

MIST
+5.67%
Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025

MONTREAL and CHARLOTTE, N.C., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced further details on its in-person and virtual Commercial Launch Plan investor event to take place in New York on Tuesday, February 25, 2025 from 10:30 AM to 12:30 PM ET. Investors planning to attend the in-person event are required to register in advance.

GlobeNewswire last month

MIST
+5.67%
Loss-Making Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Expected To Breakeven In The Medium-Term

Milestone Pharmaceuticals Inc. ( NASDAQ:MIST ) is possibly approaching a major achievement in its business, so we would...

Simply Wall St. last month

MIST
+5.67%
Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC

- PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) - Commercial capabilities build out in process, with proposed launch in PSVT targeted for mid-2025 - Plans to initiate Phase 3 Study in AFib-RVR in H1 2025 MONTREAL and CHARLOTTE, N.C., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medic

GlobeNewswire 2 months ago

MIST
+5.67%
Milestone Pharmaceuticals to Present at the Piper Sandler 36th Annual Healthcare Conference

MONTREAL and CHARLOTTE, N.C., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto, and Chief Commercial Officer, Lorenz Muller, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024, at 10:30 a.m. Eastern Time. A live webcast of the fireside chat will be available to conference participants. If you are interested in viewing the fireside chat or meeting with the

GlobeNewswire 4 months ago

MIST
+5.67%
After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook is Bright

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

Zacks 4 months ago

MIST
+5.67%
Milestone Pharmaceuticals: Q3 Earnings Snapshot

MONTREAL (AP) — Milestone Pharmaceuticals Inc. MIST) on Tuesday reported a loss of $9.4 million in its third quarter. The Montreal-based company said it had a loss of 14 cents per share.

Associated Press Finance 4 months ago

MIST
+5.67%
Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

NDA for CARDAMYST™ in PSVT under review by FDA; PDUFA March 27, 2025MONTREAL and CHARLOTTE, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the third quarter ended September 30, 2024 and provided a corporate update. “Our primary focus at Milestone is preparing for potential FDA approval of CARDAMYST (etripamil) nasal spray for the management of PSVT,” said Joseph Oliveto, President and Chief Executive Officer of Mileston

GlobeNewswire 4 months ago

MIST
+5.67%
Individual investors account for 54% of Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) ownership, while institutions account for 46%

Key Insights The considerable ownership by individual investors in Milestone Pharmaceuticals indicates that they...

Simply Wall St. 5 months ago

MIST
+5.67%

Performance Overview

Return	MIST	S&P 500 (^GSPC)
YTD	-65.97%	-3.58%
1-Year	-55.38%	+8.94%
3-Year	-88.28%	+24.75%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Milestone Pharmaceuticals Inc. (MIST)

MIST Stock Falls 66% Following Complete Response Letter for Cardamyst

Milestone Pharmaceuticals downgraded to Hold from Buy at TD Cowen

TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty

Milestone CRL affirms integrity of clinical data, says H.C. Wainwright

FDA Issues Complete Response Letter for Etripamil for PSVT

Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology

Milestone Pharmaceuticals: Q4 Earnings Snapshot

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

Milestone Pharmaceuticals Gets Notice of Allowance for US Patent on Etripamil Nasal Spray

Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil

Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025

Loss-Making Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Expected To Breakeven In The Medium-Term

Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC

Milestone Pharmaceuticals to Present at the Piper Sandler 36th Annual Healthcare Conference

After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook is Bright

Milestone Pharmaceuticals: Q3 Earnings Snapshot

Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Individual investors account for 54% of Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) ownership, while institutions account for 46%

Performance Overview